Biovinc, LLC

Pasadena, CA

UEI
NNEJMJ7KDAF1
CAGE
70D47
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
2265 E Foothill Blvd, Pasadena, CA 91107, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Lab research compounds VA25017P3023 Veterans Integrated Service Network 10 (VHA) $14,550
5-FAM-ZOL 3X1000NMOL VA25017P0838 Veterans Integrated Service Network 10 (VHA) $14,450
Research compounds VA25116P1938 Veterans Integrated Service Network 10 (VHA) $16,050

Grant awards

Award Agency Obligated Awarded
A novel bone targeted antibiotic therapy for the treatment of infected fractures R44AI175069 National Institute of Allergy and Infectious Diseases (NIH) $7,472,643
Bone metastasis specific 18F pet imaging probe for breast cancer R41CA235996 National Cancer Institute (NIH) $225,000
Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis R43AR073727 National Insititue of Arthritis and Musculoskeletal and Skin Diseases (NIH) $225,000
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy R44AI125060 National Institute of Allergy and Infectious Diseases (NIH) $5,903,326
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy R43AI125060 National Institute of Allergy and Infectious Diseases (NIH) $180,807

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
University Of Massachusetts Medical School The design and syntheses of the novel bisphosphonate-linked FAK inhibitor conjugates will be performed at BioVinc LLC, Pasadena, CA (BioVinc). As supported by… R21AR079633 $46,200

Similar vendors

Vendor Location Primary NAICS
Quercus Molecular Design, LLC UEI ZHH5N3KV48A5 Avon, CT 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Nostopharma LLC UEI FKVPNPQK64H8 Rockville, MD 541713 Research and Development in Nanotechnology
Ortholevo, Inc. UEI P3HTBAK4HNC4 Lynnfield, MA 325412 Pharmaceutical Preparation Manufacturing
Arietis Corporation UEI DCSGCN3N8D87 Boston, MA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
WNT Scientific LLC UEI CZVHJRF9T6H3 Rochester, NY 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Biovinc, LLC is an entity registered as a for-profit limited liability company focused on developing novel bone-targeted drug delivery platforms and treatments for bone-related diseases. It has been registered to receive federal awards since 2013.

Biovinc, LLC has received prime federal grant awards from the National Institutes of Health (NIH) for projects such as developing a novel bone-targeted antibiotic therapy for treating infected fractures, and designing bone metastasis-specific PET imaging probes for breast cancer. One recent $296,779 award from the National Institute of Allergy and Infectious Diseases aimed to identify a clinical development candidate and conduct necessary nonclinical studies to advance a lead compound, a bone-targeted bisphosphonate-fluoroquinolone conjugate, toward an IND application for human safety trials as a treatment for infected delayed/non-union fractures. Another $225,000 grant from the National Cancer Institute supported work on developing an 18F PET imaging probe specifically for imaging bone metastases in breast cancer. Biovinc has also received a sub-grant award from the University of Massachusetts Medical School to design and synthesize novel bisphosphonate-linked FAK inhibitor conjugates as tools to study integrin/FAK signaling in osteocytes and as potential drug leads for treating disuse bone loss.

Quick answers

Is Biovinc, LLC registered in SAM.gov?

Yes. Biovinc, LLC's SAM.gov registration is active through March 6, 2027.

What is Biovinc, LLC's most recent federal award?

Biovinc, LLC's most recent federal grant award is A novel bone targeted antibiotic therapy for the treatment of infected fractures (R44AI175069), from National Institute of Allergy and Infectious Diseases (NIH), on March 3, 2023.

On GovTribe

See Biovinc, LLC's full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login